Article
Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
Haematologica - 1 Mar 2021
Vantyghem Sophie, Peterlin Pierre, Thépot Sylvain, Ménard Audrey, Dubruille Viviane, Debord Camille, Guillaume Thierry, Garnier Alice, Le Bourgeois Amandine, Wuilleme Soraya, Godon Catherine, Theisen Olivier, Eveillard Marion, Delaunay Jacques, Maisonneuve Hervé, Morineau Nadine, Villemagne Bruno, Vigouroux Stéphane, Subiger François, Lestang Elsa, Loirat Marion, Parcelier Anne, Godmer Pascal, Mercier Mélanie, Trebouet Adrien, Luque Paz Damien, Le Calloch Ronan, Le Clech Lenaig, Bossard Céline, Moreau Anne, Ugo Valérie, Hunault Mathilde, Moreau Philippe, Le Gouill Steven, Chevallier Patrice, Béné Marie C, Le Bris Yannick
Abstract excerpt
Next-generation sequencing (NGS) is used to investigate the presence of somatic mutations. The utility of incorporating routine sequencing to guide diagnosis and therapeutic decisions remains unclear. We report the findings of an observational, multicenter study that aimed to assess the impact of somatic mutation testing by NGS in a reallife setting of chronic myeloid malignancies. A total of 177 patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.